Regeneron Pharmaceuticals discovers and develops medicines across multiple therapeutic areas including eye disease, allergies, inflammation, cardiovascular conditions, metabolic disorders, neurological diseases, infections, cancer, and blood disorders. The company manufactures and sells several approved medications such as EYLEA for macular degeneration and diabetic eye conditions, Dupixent for atopic dermatitis and asthma, Libtayo for skin cancer, Praluent for high cholesterol, and Kevzara for rheumatoid arthritis. Regeneron also maintains partnerships with other biotechnology and pharmaceutical firms to advance gene-editing therapies, RNA-based treatments, and radiopharmaceutical products in development.
1Y: 789.45 (+32.5%) · range 552.68–852.03
entry readiness 17 · NOT READY · exit proximity 0
Value area 590.83–751.94 · 14% of 120d volume overhead · clean runway
| Source | Score | Last seen |
|---|---|---|
| earnings-surprise | 0.033 | Aug 28, 2026 |
none
IMPROVING · rank 12 · inflow
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -1.48% | -1.48% | 1/20d |
| 40d | -1.48% | -1.48% | 1/40d |